<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">helmholtzeyeinstitute</journal-id><journal-title-group><journal-title xml:lang="ru">Российский офтальмологический журнал</journal-title><trans-title-group xml:lang="en"><trans-title>Russian Ophthalmological Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2072-0076</issn><issn pub-type="epub">2587-5760</issn><publisher><publisher-name>Real time Publishers</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21516/2072-0076-2025-18-4-190-195</article-id><article-id custom-type="elpub" pub-id-type="custom">helmholtzeyeinstitute-1975</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Целесообразность старта гипотензивной терапии первичной глаукомы с фиксированной комбинации простагландина и тимолола</article-title><trans-title-group xml:lang="en"><trans-title>Feasibility of a prostaglandin-timolol fixed combination first-line treatment of primary glaucoma</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6922-0464</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>С. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>S. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Сергей Юрьевич Петров — д-р мед. наук, начальник отдела глаукомы</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Sergey Yu. Petrov — Dr. of Med. Sci., head of the glaucoma department</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p></bio><email xlink:type="simple">glaucomatosis@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8090-6034</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Маркелова</surname><given-names>О. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Markelova</surname><given-names>O. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Оксана Игоревна Маркелова — младший научный сотрудник отдела глаукомы</p><p>ул. Садовая-Черногрязская, д. 14/19, Москва, 105062</p></bio><bio xml:lang="en"><p>Oksana I. Markelova — junior researcher, glaucoma department</p><p>14/19, Sadovaya-Chernogryazskaya St., Moscow, 105062</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «НМИЦ глазных болезней им. Гельмгольца» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Helmholtz National Medical Research Center of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>09</day><month>01</month><year>2026</year></pub-date><volume>18</volume><issue>4</issue><fpage>190</fpage><lpage>195</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Петров С.Ю., Маркелова О.И., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Петров С.Ю., Маркелова О.И.</copyright-holder><copyright-holder xml:lang="en">Petrov S.Y., Markelova O.I.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://roj.igb.ru/jour/article/view/1975">https://roj.igb.ru/jour/article/view/1975</self-uri><abstract><p>Глаукома является наиболее частой причиной необратимой слепоты во всем мире. Причинами высокого растущего уровня инвалидизации населения вследствие глаукомы являются низкий диагностический охват населения, назначение некорректных схем местной гипотензивной терапии и низкий уровень приверженности лечению глаукомных пациентов. Классическая рекомендованная стартовая терапия с одного препарата на практике зачастую не позволяет достигнуть целевых значений офтальмотонуса при развитой и далеко зашедшей стадии глаукомы с высоким стартовым уровнем внутриглазного давления (ВГД), что, согласно клиническим рекомендациям, является показанием для назначения комбинированной терапии. Начальная терапия с фиксированной комбинации латанопроста и тимола в данной клинической ситуации позволяет добиться значимого снижения ВГД и повысить приверженность пациента за счет оптимизации числа закапываний, уменьшения суммарной стоимости лечения, снижения общего объема инстиллируемого консерванта, отсутствия эффекта вымывания и ожидания между закапыванием двух препаратов.</p></abstract><trans-abstract xml:lang="en"><p>Glaucoma is the most common cause of irreversible blindness worldwide. The reasons for the high and growing level of blindness due to glaucoma are low diagnostic population coverage, the incorrect hypotensive therapy and low glaucoma patient’s adherence. In practice, the recommended initial monotherapy does not allow achieving target IOP at moderate and advanced glaucoma with a high IOP level, which, according to clinical guidelines, is an indication for the initial combination therapy. Starting with a latanoprost-timolol fixed combination allows achieving a significant IOP decrease and increasing patient compliance by optimizing the number of instillations, reducing the total treatment cost, the total preservative volume, the absence of a washout effect and waiting between instillation of two drugs.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>глаукома</kwd><kwd>фиксированная комбинация</kwd><kwd>приверженность</kwd><kwd>стартовая терапия</kwd><kwd>латанопрост</kwd><kwd>тимолол</kwd></kwd-group><kwd-group xml:lang="en"><kwd>glaucoma</kwd><kwd>fixed combination</kwd><kwd>adherence</kwd><kwd>initial therapy</kwd><kwd>latanoprost</kwd><kwd>timolol</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90 (3): 262–7. doi: 10.1136/bjo.2005.081224</mixed-citation><mixed-citation xml:lang="en">Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90 (3): 262–7. doi: 10.1136/bjo.2005.081224</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Stuart KV, de Vries VA, Schuster AK, et al. Prevalence of glaucoma in Europe and projections to 2050: Findings from the European Eye Epidemiology (E3) Consortium. Ophthalmology. 2025 Oct; 132 (10): 1114–24. doi: 10.1016/j.ophtha.2025.06.002</mixed-citation><mixed-citation xml:lang="en">Stuart KV, de Vries VA, Schuster AK, et al. Prevalence of glaucoma in Europe and projections to 2050: Findings from the European Eye Epidemiology (E3) Consortium. Ophthalmology. 2025 Oct; 132 (10): 1114–24. doi: 10.1016/j.ophtha.2025.06.002</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Jonas J.B., Aung T., Bourne R.R., et al. Glaucoma. Lancet. 2017; 390 (10108): 2183–93. doi: 10.1016/S0140-6736(17)31469-1</mixed-citation><mixed-citation xml:lang="en">Jonas J.B., Aung T., Bourne R.R., et al. Glaucoma. Lancet. 2017; 390 (10108): 2183–93. doi: 10.1016/S0140-6736(17)31469-1</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">World report on vision. World Health Organization. 2019 [29.02.2024]. Available from: https://cdn.who.int/media/docs/default-source/blindness-and-visualimpairment/9789241516570-eng.pdf?sfvrsn=dd15adbb_3</mixed-citation><mixed-citation xml:lang="en">World report on vision. World Health Organization. 2019 [29.02.2024]. Available from: https://cdn.who.int/media/docs/default-source/blindness-and-visualimpairment/9789241516570-eng.pdf?sfvrsn=dd15adbb_3</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 2081–90. doi: 10.1016/j.ophtha.2014.05.013</mixed-citation><mixed-citation xml:lang="en">Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014; 121 (11): 2081–90. doi: 10.1016/j.ophtha.2014.05.013</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Нероев В.В., Михайлова Л.А., Малишевская Т.Н., Петров С.Ю., Филиппова О.М. Эпидемиология глаукомы в Российской Федерации. Российский офтальмологический журнал. 2024; 17 (3): 7–12. doi: 10.21516/2072-0076-2024-17-3-7-12</mixed-citation><mixed-citation xml:lang="en">Neroev V.V., Mikhaylova L.A., Malishevskaya T.N., Petrov S.Yu., Filippova O.M. Glaucoma epidemiology in the Russian Federation. Russian ophthalmological journal. 2024; 17 (3): 7–12 (In Russ.). doi: 10.21516/2072-0076-2024-17-3-7-12</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Asia Pacific Glaucoma Guidelines: Kugler Publications; 2016. https://www.apglaucomasociety.org/2024-asia-pacific-glaucoma-guidelines</mixed-citation><mixed-citation xml:lang="en">Asia Pacific Glaucoma Guidelines: Kugler Publications; 2016. https://www.apglaucomasociety.org/2024-asia-pacific-glaucoma-guidelines</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">ICO Guidelines for Glaucoma Eye Care: International Council of Ophthalmology; 2015. https://icoph.org/eye-care-delivery/glaucoma/</mixed-citation><mixed-citation xml:lang="en">ICO Guidelines for Glaucoma Eye Care: International Council of Ophthalmology; 2015. https://icoph.org/eye-care-delivery/glaucoma/</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern (R). Ophthalmology. 2021; 128(1): 71-150. doi: 10.1016/j.ophtha.2020.10.022</mixed-citation><mixed-citation xml:lang="en">Gedde SJ, Vinod K, Wright MM, et al. Primary open-angle glaucoma preferred practice pattern (R). Ophthalmology. 2021; 128(1): 71-150. doi: 10.1016/j.ophtha.2020.10.022</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73 (5): 691–705. doi: 10.1111/j.1365-2125.2012.04167.x</mixed-citation><mixed-citation xml:lang="en">Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73 (5): 691–705. doi: 10.1111/j.1365-2125.2012.04167.x</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации «Глаукома первичная закрытоугольная» ID 631_2 (16.08.2024). http://avo-portal.ru/documents/fkr/KR_PZYG_21_05_2020.pdf</mixed-citation><mixed-citation xml:lang="en">Clinical Gidelines “Primary open angle glaucoma” ID 631_2 (16.08.2024) (In Russ.). http://avo-portal.ru/documents/fkr/KR_PZYG_21_05_2020.pdf</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации «Глаукома первичная открытоугольная» ID 96_2 (17.08.2024).</mixed-citation><mixed-citation xml:lang="en">Clinical Gidelines “Primary open angle glaucoma” ID 96_2 (17.08.2024) (In Russ.). http://avo-portal.ru/documents/fkr/Klinicheskie_rekomendacii_POUG_2022.pdf</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации «Глаукомы вторичные» ID 843_1 (17.12.2024). http://avo-portal.ru/doc/fkr/item/545-glaukomyvtorichnye</mixed-citation><mixed-citation xml:lang="en">Clinical Gidelines “Primary open angle glaucoma” ID 843_1 (17.12.2024) (In Russ.). http://avo-portal.ru/doc/fkr/item/545-glaukomyvtorichnye</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Клинические рекомендации «Подозрение на глаукому» ID 628_2 (09.08.2024). http://avo-portal.ru/doc/fkr/item/561-podozreniena-glaukomu</mixed-citation><mixed-citation xml:lang="en">Clinical Gidelines “Primary open angle glaucoma” ID 628_2 (09.08.2024) (In Russ.). http://avo-portal.ru/doc/fkr/item/561-podozreniena-glaukomu</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">European Glaucoma Society. Terminology and guidelines for glaucoma. 5th edition ed: Savona, Italy PubliComm; 2020. 172 p.</mixed-citation><mixed-citation xml:lang="en">European Glaucoma Society. Terminology and guidelines for glaucoma. 5th edition ed: Savona, Italy PubliComm; 2020. 172 p.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Friedman DS, Nordstrom B, Mozaffari E, Quigley H.A. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology. 2005; 112 (9): 1500–4. doi: 10.1016/j.ophtha.2005.02.030</mixed-citation><mixed-citation xml:lang="en">Friedman DS, Nordstrom B, Mozaffari E, Quigley H.A. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. Ophthalmology. 2005; 112 (9): 1500–4. doi: 10.1016/j.ophtha.2005.02.030</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Li T, Lindsley K, Rouse B, et al. Comparative Effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. Ophthalmology. 2016; 123 (1): 129–40. doi: 10.1016/j.ophtha.2015.09.005</mixed-citation><mixed-citation xml:lang="en">Li T, Lindsley K, Rouse B, et al. Comparative Effectiveness of first-line medications for primary open-angle glaucoma: A systematic review and network meta-analysis. Ophthalmology. 2016; 123 (1): 129–40. doi: 10.1016/j.ophtha.2015.09.005</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999; 106 (4): 653–62. doi: 10.1016/s0161-6420(99)90147-1</mixed-citation><mixed-citation xml:lang="en">Musch DC, Lichter PR, Guire KE, Standardi CL. The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. Ophthalmology. 1999; 106 (4): 653–62. doi: 10.1016/s0161-6420(99)90147-1</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Bourne RR. Worldwide glaucoma through the looking glass. Br J Ophthalmol. 2006; 90 (3): 253–4. doi: 10.1136/bjo.2005.083527</mixed-citation><mixed-citation xml:lang="en">Bourne RR. Worldwide glaucoma through the looking glass. Br J Ophthalmol. 2006; 90 (3): 253–4. doi: 10.1136/bjo.2005.083527</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Bourne RR, Taylor HR, Flaxman SR, et al. Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990–2010: A meta-analysis. PLoS One. 2016; 11 (10): e0162229. doi: 10.1371/journal.pone.0162229</mixed-citation><mixed-citation xml:lang="en">Bourne RR, Taylor HR, Flaxman SR, et al. Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990–2010: A meta-analysis. PLoS One. 2016; 11 (10): e0162229. doi: 10.1371/journal.pone.0162229</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Shaikh Y, Yu F, Coleman AL. Burden of undetected and untreated glaucoma in the United States. Am J Ophthalmol. 2014; 158 (6): 1121–9 e1. doi: 10.1016/j.ajo.2014.08.023</mixed-citation><mixed-citation xml:lang="en">Shaikh Y, Yu F, Coleman AL. Burden of undetected and untreated glaucoma in the United States. Am J Ophthalmol. 2014; 158 (6): 1121–9 e1. doi: 10.1016/j.ajo.2014.08.023</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Topouzis F, Coleman AL, Harris A, et al. Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study. Am J Ophthalmol. 2008; 145 (2): 327–35. doi: 10.1016/j.ajo.2007.09.013</mixed-citation><mixed-citation xml:lang="en">Topouzis F, Coleman AL, Harris A, et al. Factors associated with undiagnosed open-angle glaucoma: the Thessaloniki Eye Study. Am J Ophthalmol. 2008; 145 (2): 327–35. doi: 10.1016/j.ajo.2007.09.013</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Glaucoma Treatment Market. Global Market Insight . 2024 [07.07.2025]. Available at: https://www.gminsights.com/industry-analysis/glaucomatreatment-market</mixed-citation><mixed-citation xml:lang="en">Glaucoma Treatment Market. Global Market Insight . 2024 [07.07.2025]. Available at: https://www.gminsights.com/industry-analysis/glaucomatreatment-market</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Егоров Е.А., Куроедов А.В. Отдельные клинико-эпидемиологические характеристики глаукомы в странах СНГ и Грузии. Результаты многоцентро вого открытого ретроспективного исследования (часть 1). РМЖ. Клиническая офтальмология. 2011; 12 (3): 97–100.</mixed-citation><mixed-citation xml:lang="en">Egorov E.A., Kuroedov A.V. Clinical and epidemiological characteristics of glaucoma in CIS and Georgia. Results of multicenter opened retrospective trial (part 1). Russian journal of clinical ophthalmology. 2011; 12 (3): 97–100 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Егоров Е.А., Куроедов А.В. Отдельные клинико-эпидемиологические характеристики глаукомы в странах СНГ и Грузии. Результаты многоцентро вого открытого ретроспективного исследования (часть 2). РМЖ. Клиническая офтальмология. 2012; 13 (1): 19–22.</mixed-citation><mixed-citation xml:lang="en">Egorov E.A., Kuroedov A.V. Clinical and epidemiological characteristics of glaucoma in CIS and Georgia. Results of multicenter opened retrospective trial (part 2). Russian journal of clinical ophthalmology. 2012; 13 (1): 19–22 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Абышева Л.Д., Александров А.С., Арапиев М.У. и др. Оптимизация лечебно-диагностического процесса у пациентов с первичной открытоугольной глаукомой. Национальный журнал глаукома. 2016; 15 (2): 19–34.</mixed-citation><mixed-citation xml:lang="en">Abysheva L.D., Alexandrov A.S., Arapiev M.U., et al. Optimization of diagnosis and treatment options in primary open-angle glaucoma patients. Russian journal of glaucoma. 2016; 15 (2): 19–34 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Hoevenaars JG, Schouten JS, van den Borne B, Beckers HJ, Webers CA. Will improvement of knowledge lead to improvement of compliance with glaucoma medication? Acta Ophthalmol. 2008; 86 (8): 849–55. doi: 10.1111/j.1755-3768.2007.01161.x</mixed-citation><mixed-citation xml:lang="en">Hoevenaars JG, Schouten JS, van den Borne B, Beckers HJ, Webers CA. Will improvement of knowledge lead to improvement of compliance with glaucoma medication? Acta Ophthalmol. 2008; 86 (8): 849–55. doi: 10.1111/j.1755-3768.2007.01161.x</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008; 53 Suppl1 (S57-68). doi: 10.1016/j.survophthal.2008.08.002</mixed-citation><mixed-citation xml:lang="en">Schwartz GF, Quigley HA. Adherence and persistence with glaucoma therapy. Surv Ophthalmol. 2008; 53 Suppl1 (S57-68). doi: 10.1016/j.survophthal.2008.08.002</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Moore SG, Richter G, Modjtahedi BS. Factors affecting glaucoma medication adherence and interventions to improve adherence: A narrative review. Ophthalmol Ther. 2023; 12 (6): 2863–80. doi: 10.1007/s40123-023-00797-8</mixed-citation><mixed-citation xml:lang="en">Moore SG, Richter G, Modjtahedi BS. Factors affecting glaucoma medication adherence and interventions to improve adherence: A narrative review. Ophthalmol Ther. 2023; 12 (6): 2863–80. doi: 10.1007/s40123-023-00797-8</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Нероев В.В., Золотарев А.В., Карлова Е.В. и др. Влияние приверженности к лечению на прогрессирование первичной открытоугольной глаукомы у пациентов в условиях клинической практики. Вестник офтальмологии. 2019; 135 (6): 42–51. doi: 10.17116/oftalma201913506142</mixed-citation><mixed-citation xml:lang="en">Neroyev V.V., Zolotarev A.V., Karlova E.V., et al. Influence of treatment adherence on the progression of primary openangle glaucoma in clinical setting. Vestnik oftal’mologii. 2019; 135 (6): 42–51 (In Russ.). doi: 10.17116/oftalma201913506142</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Stryker JE, Beck AD, Primo SA, et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma. 2010; 19 (1): 66–72. doi: 10.1097/IJG.0b013e31819c4679</mixed-citation><mixed-citation xml:lang="en">Stryker JE, Beck AD, Primo SA, et al. An exploratory study of factors influencing glaucoma treatment adherence. J Glaucoma. 2010; 19 (1): 66–72. doi: 10.1097/IJG.0b013e31819c4679</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Malewicz K, Pender A, Chabowski M, Jankowska-Polanska B. Impact of sociodemographic and psychological factors on adherence to glaucoma treatment — A cross-sectional study. Clin Ophthalmol. 2024; 18: 2503–20. doi: 10.2147/OPTH.S475812</mixed-citation><mixed-citation xml:lang="en">Malewicz K, Pender A, Chabowski M, Jankowska-Polanska B. Impact of sociodemographic and psychological factors on adherence to glaucoma treatment — A cross-sectional study. Clin Ophthalmol. 2024; 18: 2503–20. doi: 10.2147/OPTH.S475812</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Корнеева А.В., Куроедов А.В., Завадский П.Ч. и др. Приверженность гипотензивной терапии при глаукоме: мнение пациентов о ключевых факторах низкой степени комплаенса. Результаты многоцентрового интерактивного научно-аналитического исследования. Национальный журнал глаукома. 2020; 19 (3): 12–21. doi: 10.25700/NJG.2020.03.02</mixed-citation><mixed-citation xml:lang="en">Korneeva A.V., Kuroyedov A.V., Zavadski P.Ch., et al. Adherence to glaucoma hypotensive therapy: patients' opinions on key factors of low compliance. Analytical multi-central study results. National journal of glaucoma. 2020; 19 (3): 12–21 (In Russ.). doi: 10.25700/NJG.2020.03.02</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed Travoprost 0.004%/Timolol 0.5% for glaucoma or ocular hypertension: A randomized trial. Am J Ophthalmol. 2017; 176: 61–9. doi: 10.1016/j.ajo.2016.12.002</mixed-citation><mixed-citation xml:lang="en">Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed Travoprost 0.004%/Timolol 0.5% for glaucoma or ocular hypertension: A randomized trial. Am J Ophthalmol. 2017; 176: 61–9. doi: 10.1016/j.ajo.2016.12.002</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Poleon S, Twa M, Schoenberger-Godwin YM, Fifolt M, Racette L. A taxonomy of behavior change techniques for improving medication adherence in primary open-angle glaucoma. J Ophthalmol. 2025; 2025: 9917724. doi: 10.1155/joph/9917724</mixed-citation><mixed-citation xml:lang="en">Poleon S, Twa M, Schoenberger-Godwin YM, Fifolt M, Racette L. A taxonomy of behavior change techniques for improving medication adherence in primary open-angle glaucoma. J Ophthalmol. 2025; 2025: 9917724. doi: 10.1155/joph/9917724</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Babic N. Fixed combinations of glaucoma medications. Srp Arh Celok Lek. 2015; 143 (9–10): 626-31. doi: 10.2298/sarh1510626b</mixed-citation><mixed-citation xml:lang="en">Babic N. Fixed combinations of glaucoma medications. Srp Arh Celok Lek. 2015; 143 (9–10): 626-31. doi: 10.2298/sarh1510626b</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Wang T, Cao L, Jiang Q, Zhang T. Topical medication therapy for glaucoma and ocular hypertension. Front Pharmacol. 2021; 12:749858. doi: 10.3389/fphar.2021.749858</mixed-citation><mixed-citation xml:lang="en">Wang T, Cao L, Jiang Q, Zhang T. Topical medication therapy for glaucoma and ocular hypertension. Front Pharmacol. 2021; 12:749858. doi: 10.3389/fphar.2021.749858</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Konstas AG, Schmetterer L, Costa VP, et al. Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opin Drug Saf. 2020; 19 (11): 1445–60. doi: 10.1080/14740338.2020.1826928</mixed-citation><mixed-citation xml:lang="en">Konstas AG, Schmetterer L, Costa VP, et al. Current and emerging fixed combination therapies in glaucoma: a safety and tolerability review. Expert Opin Drug Saf. 2020; 19 (11): 1445–60. doi: 10.1080/14740338.2020.1826928</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995; 26 (3): 233–6. PMID: 7651690.</mixed-citation><mixed-citation xml:lang="en">Patel SC, Spaeth GL. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg. 1995; 26 (3): 233–6. PMID: 7651690.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006; 113 (3): 431–6. doi: 10.1016/j.ophtha.2005.10.034</mixed-citation><mixed-citation xml:lang="en">Sleath B, Robin AL, Covert D, et al. Patient-reported behavior and problems in using glaucoma medications. Ophthalmology. 2006; 113 (3): 431–6. doi: 10.1016/j.ophtha.2005.10.034</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006; 17 (2): 190–5. doi: 10.1097/01.icu.0000193078.47616.aa</mixed-citation><mixed-citation xml:lang="en">Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol. 2006; 17 (2): 190–5. doi: 10.1097/01.icu.0000193078.47616.aa</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Higginbotham EJ. Ocular Hypertension Treatment Study. Arch Ophthalmol. 2009; 127 (2): 213–5. doi: 10.1001/archophthalmol.2008.599</mixed-citation><mixed-citation xml:lang="en">Higginbotham EJ. Ocular Hypertension Treatment Study. Arch Ophthalmol. 2009; 127 (2): 213–5. doi: 10.1001/archophthalmol.2008.599</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120 (6): 701–13; discussion 829–30. doi: 10.1001/archopht.120.6.701</mixed-citation><mixed-citation xml:lang="en">Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120 (6): 701–13; discussion 829–30. doi: 10.1001/archopht.120.6.701</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108 (11): 1943–53. doi: 10.1016/s0161-6420(01)00873-9</mixed-citation><mixed-citation xml:lang="en">Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology. 2001; 108 (11): 1943–53. doi: 10.1016/s0161-6420(01)00873-9</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">DuBiner HB, Mroz M, Shapiro AM, Dirks MS, Brimonidine vs. Latanoprost Study G. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a threemonth, multicenter, randomized, double-masked, parallel-group trial. Clin Ther. 2001; 23 (12): 1969–83. doi: 10.1016/s0149-2918(01)80150-8</mixed-citation><mixed-citation xml:lang="en">DuBiner HB, Mroz M, Shapiro AM, Dirks MS, Brimonidine vs. Latanoprost Study G. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a threemonth, multicenter, randomized, double-masked, parallel-group trial. Clin Ther. 2001; 23 (12): 1969–83. doi: 10.1016/s0149-2918(01)80150-8</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol. 2000; 238 (1): 19–23. doi: 10.1007/s004170050003</mixed-citation><mixed-citation xml:lang="en">Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension.A 3-month randomised study. Graefes Arch Clin Exp Ophthalmol. 2000; 238 (1): 19–23. doi: 10.1007/s004170050003</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Jampel HD, Bacharach J, Sheu WP, et al. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol. 2002; 134 (6): 863–71. doi: 10.1016/s0002-9394(02)01820-2</mixed-citation><mixed-citation xml:lang="en">Jampel HD, Bacharach J, Sheu WP, et al. Randomized clinical trial of latanoprost and unoprostone in patients with elevated intraocular pressure. Am J Ophthalmol. 2002; 134 (6): 863–71. doi: 10.1016/s0002-9394(02)01820-2</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Kampik A, Arias-Puente A, O'Brart DP, Vuori ML, European Latanoprost Study G. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma. 2002; 11 (2): 90–6. doi: 10.1097/00061198-200204000-00003</mixed-citation><mixed-citation xml:lang="en">Kampik A, Arias-Puente A, O'Brart DP, Vuori ML, European Latanoprost Study G. Intraocular pressure-lowering effects of latanoprost and brimonidine therapy in patients with open-angle glaucoma or ocular hypertension: a randomized observer-masked multicenter study. J Glaucoma. 2002; 11 (2): 90–6. doi: 10.1097/00061198-200204000-00003</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001; 131 (5): 631–5. doi: 10.1016/s0002-9394(00)00902-8</mixed-citation><mixed-citation xml:lang="en">Stewart WC, Day DG, Stewart JA, Schuhr J, Latham KE. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001; 131 (5): 631–5. doi: 10.1016/s0002-9394(00)00902-8</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011; 20 (4): 215–22. doi: 10.1097/IJG.0b013e3181e08121</mixed-citation><mixed-citation xml:lang="en">Alm A, Grunden JW, Kwok KK. Five-year, multicenter safety study of fixed-combination latanoprost/timolol (Xalacom) for open-angle glaucoma and ocular hypertension. J Glaucoma. 2011; 20 (4): 215–22. doi: 10.1097/IJG.0b013e3181e08121</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Lou H, Wang H, Zong Y, Cheng JW, Wei RL. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res Opin. 2015; 31 (6): 1139–47. doi: 10.1185/03007995.2015.1039504</mixed-citation><mixed-citation xml:lang="en">Lou H, Wang H, Zong Y, Cheng JW, Wei RL. Efficacy and tolerability of prostaglandin-timolol fixed combinations: an updated systematic review and meta-analysis. Curr Med Res Opin. 2015; 31 (6): 1139–47. doi: 10.1185/03007995.2015.1039504</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Rigollet JP, Ondategui JA, Pasto A, Lop L. Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate. Clin Ophthalmol. 2011; 5: 187–91. doi: 10.2147/OPTH.S16666</mixed-citation><mixed-citation xml:lang="en">Rigollet JP, Ondategui JA, Pasto A, Lop L. Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate. Clin Ophthalmol. 2011; 5: 187–91. doi: 10.2147/OPTH.S16666</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2004; 5 (4): 909–21. doi: 10.1517/14656566.5.4.909</mixed-citation><mixed-citation xml:lang="en">Feldman RM. An evaluation of the fixed-combination of latanoprost and timolol for use in open-angle glaucoma and ocular hypertension. Expert Opin Pharmacother. 2004; 5 (4): 909–21. doi: 10.1517/14656566.5.4.909</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative G. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002; 120 (7): 915–22. doi: 10.1001/archopht.120.7.915</mixed-citation><mixed-citation xml:lang="en">Higginbotham EJ, Feldman R, Stiles M, Dubiner H, Fixed Combination Investigative G. Latanoprost and timolol combination therapy vs monotherapy: one-year randomized trial. Arch Ophthalmol. 2002; 120 (7): 915–22. doi: 10.1001/archopht.120.7.915</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Inoue K, Fujimoto T, Higa R, et al. Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy. Clin Ophthalmol. 2012; 6: 771–5. doi: 10.2147/OPTH.S31085</mixed-citation><mixed-citation xml:lang="en">Inoue K, Fujimoto T, Higa R, et al. Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from latanoprost 0.005% monotherapy. Clin Ophthalmol. 2012; 6: 771–5. doi: 10.2147/OPTH.S31085</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J Glaucoma. 2009; 18 (9): 652–7. doi: 10.1097/IJG.0b013e31819c49d4</mixed-citation><mixed-citation xml:lang="en">Cheng JW, Cai JP, Li Y, Wei RL. A meta-analysis of topical prostaglandin analogs in the treatment of chronic angle-closure glaucoma. J Glaucoma. 2009; 18 (9): 652–7. doi: 10.1097/IJG.0b013e31819c49d4</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009; 116 (7): 1243–9. doi: 10.1016/j.ophtha.2009.01.036</mixed-citation><mixed-citation xml:lang="en">Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009; 116 (7): 1243–9. doi: 10.1016/j.ophtha.2009.01.036</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Tabet R, Stewart WC, Feldman R, Konstas AG. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol. 2008; 53 Suppl1: S85-92. doi: 10.1016/j.survophthal.2008.08.011</mixed-citation><mixed-citation xml:lang="en">Tabet R, Stewart WC, Feldman R, Konstas AG. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv Ophthalmol. 2008; 53 Suppl1: S85-92. doi: 10.1016/j.survophthal.2008.08.011</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013; 29 (4): 382–9. doi: 10.1089/jop.2012.0186</mixed-citation><mixed-citation xml:lang="en">Quaranta L, Biagioli E, Riva I, et al. Prostaglandin analogs and timolol-fixed versus unfixed combinations or monotherapy for open-angle glaucoma: a systematic review and meta-analysis. J Ocul Pharmacol Ther. 2013; 29 (4): 382–9. doi: 10.1089/jop.2012.0186</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Webers CA, Beckers HJ, Zeegers MP, et al. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical beta-blocker therapy: a systematic review and meta-analysis. Ophthalmology. 2010; 117 (11): 2067-74 e1-6. doi: 10.1016/j.ophtha.2010.03.024</mixed-citation><mixed-citation xml:lang="en">Webers CA, Beckers HJ, Zeegers MP, et al. The intraocular pressure-lowering effect of prostaglandin analogs combined with topical beta-blocker therapy: a systematic review and meta-analysis. Ophthalmology. 2010; 117 (11): 2067-74 e1-6. doi: 10.1016/j.ophtha.2010.03.024</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Hamacher T, Schinzel M, Scholzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 2004; 88 (10): 1295–8. doi: 10.1136/bjo.2004.043232</mixed-citation><mixed-citation xml:lang="en">Hamacher T, Schinzel M, Scholzel-Klatt A, et al. Short term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from monotherapies and adjunctive therapies. Br J Ophthalmol. 2004; 88 (10): 1295–8. doi: 10.1136/bjo.2004.043232</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Stewart WC, Stewart JA, Day D, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. 2003; 81 (3): 242–6. doi: 10.1034/j.1600-0420.2003.00065.x</mixed-citation><mixed-citation xml:lang="en">Stewart WC, Stewart JA, Day D, Sharpe ED. Efficacy and safety of timolol maleate/latanoprost fixed combination versus timolol maleate and brimonidine given twice daily. Acta Ophthalmol Scand. 2003; 81 (3): 242–6. doi: 10.1034/j.1600-0420.2003.00065.x</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Magacho L, Reis R, Shetty RK, Santos LC, Avila MP. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology. 2006; 113 (3): 442–5. doi: 10.1016/j.ophtha.2005.11.011</mixed-citation><mixed-citation xml:lang="en">Magacho L, Reis R, Shetty RK, Santos LC, Avila MP. Efficacy of latanoprost or fixed-combination latanoprost-timolol in patients switched from a combination of timolol and a nonprostaglandin medication. Ophthalmology. 2006; 113 (3): 442–5. doi: 10.1016/j.ophtha.2005.11.011</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Апостолова А.С. Сравнительное исследование эффективности препаратов Ксалатан и Ксалаком (Pfizer, США) в лечении псевдоэксфолиативной глаукомы. Офтальмологические ведомости. 2013; 6 (3): 71–4.</mixed-citation><mixed-citation xml:lang="en">Apostolova A.S. A comparative study of Xalatan and Xalacom (Pfizer, USA) efficacy in the treatment of pseudoexfoliative glaucoma. Ophthalmology reports. 2013; 6 (3): 71–4 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Макогон С.И., Онищенко А.Л., Яценко Л.Л., Карманова О.А. Стартовая терапия в лечении впервые выявленной первичной глаукомы. Национальный журнал глаукома. 2018; 17 (2): 28–37.</mixed-citation><mixed-citation xml:lang="en">Makogon S.I., Onishchenko A.L., Yatsenko L.L., Karmanova O.A. The efficacy of first-choice therapy in the treatment of newly diagnosed primary glaucoma. Russian journal of glaucoma. 2018; 17 (2): 28–37 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Weinreb RN, Libermann J. Медикаментозное лечение глаукомы. VII Консенсус Всемирной глаукомной ассоциации. СПб.: Изд-во Н-Л; 2014.</mixed-citation><mixed-citation xml:lang="en">Weinreb R.N., Libermann J. Drug treatment of glaucoma. The 7th Consensus of the World Glaucomatous Association. SPb.: Publishing House of NL; 2014 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Макогон С.И., Макогон А.С. Особенности первичной и повторной инвалидности вследствие глаукомы у лиц старше трудоспособного возраста в Алтайском крае. Российский офтальмологический журнал. 2017; 10 (3): 42–8. doi: 10.21516/2072-0076-2017-10-3-42-48</mixed-citation><mixed-citation xml:lang="en">Makogon S.I., Makogon A.S. Primary and recurrent glaucoma-induced disability in senior working-age population in the Altai territory. Russian ophthalmological journal. 2017; 10 (3): 42–8 (In Russ.). doi: 10.21516/2072-0076-2017-10-3-42-48</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Онищенко А.Л., Исаков И.Н., Колбаско А.В., Макогон С.И. Стартовая комбинированная терапия первичной открытоугольной глаукомы. Вестник офтальмологии. 2019; 135 (2): 32–8. doi: 10.17116/oftalma201913502132</mixed-citation><mixed-citation xml:lang="en">Onishchenko A.I., Isakov I.N., Kolbasko A.V., Makogon S.I. Initial combination therapy for primary openangle glaucoma Vestnik oftal’mologii. 2019; 135 (2): 32–8 (In Russ.). doi: 10.17116/oftalma201913502132</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
